
ISBN: 978-0-12-803526-9

© Copyright 2016 Elsevier Inc.

Academic Press
CHAPTER ONE

Opportunities and Challenges for Metal Chemistry in Molecular Imaging: From Gamma Camera Imaging to PET and Multimodality Imaging

Richard Southworth, Rafael Torres Martin de Rosales, Levente K. Meszaros, Michelle T. Ma, Gregory E.D. Mullen, Gilbert Fruhwirth, Jennifer D. Young, Cinzia Imberti, Julia Bagunya-Torres, Erica Andreozzi, Philip J. Blower

Division of Imaging Sciences and Biomedical Engineering, St. Thomas Hospital, King’s College London, London, United Kingdom

1 Corresponding author: e-mail address: Philip.Blower@kcl.ac.uk

Contents

1. Introduction 2
2. Technetium-99m: Small Complexes 4
   2.1 From Serendipity to Design 4
   2.2 Tc(I)tricarbonyl 5
   2.3 Tc(V) Complexes 6
   2.4 Bioconjugates: A New Challenge 8
   2.5 Bioconjugation with Hynic 8
   2.6 Bioconjugation with Other Bifunctional Chelators 10
   2.7 Bioconjugation with the “Tricarbonyl Core” Tc(CO)3+ 10
   2.8 Bioconjugation by Direct Labeling Via Cysteine 12
   2.9 Rhenium Analogs 13
   2.10 Summary: Challenges in Tc-99m Chemistry 13
3. The Transition Toward PET 14
   3.1 The Need for Metallic Positron Emitters 14
   3.2 Gallium-68: “The New Technetium-99m” 14
   3.3 Zirconium-89: “The New Indium-111”—ImmunoPET and Cell Tracking 17
4. Copper: Exploiting Redox Chemistry 19
   4.1 Copper Isotopes and Bioconjugates 19
   4.2 Bioreductive Trapping—Imaging Blood Flow and Hypoxia 21
   4.3 Cell Tracking with Copper 28
   4.4 Copper Trafficking Pathways in Health and Disease 29
5. Inorganic Elements as Binding Sites for 18F-Fluoride 31
Abstract

The development of medical imaging is a highly multidisciplinary endeavor requiring the close cooperation of clinicians, physicists, engineers, biologists, and chemists to identify capabilities, conceive challenges and solutions and apply them in the clinic. The chemistry described in this chapter illustrates how synergistic advances in these areas drive the technology and its applications forward, with each discipline producing innovations that in turn drive innovations in the others. The main thread running through the chapter is the shift from single photon radionuclide imaging toward PET, and in turn the emerging shift from PET/CT toward PET/MRI and further, combination of these with optical imaging. Chemistry to support these transitions is exemplified by building on a summary of the status quo, and recent developments, in technetium-99m chemistry for SPECT imaging, followed by a report of recent developments to support clinical application of short-lived (Ga-68) and long-lived (Zr-89) positron-emitting isotopes, copper isotopes for PET imaging, and combined modality imaging agents based on radiolabeled iron oxide-based nanoparticles.

1. INTRODUCTION

Nuclear medicine is a primarily diagnostic medical imaging specialty in which tracer molecules targeted toward specific molecular processes are labeled with radioisotopes, and used to spatially and temporally map physiological and molecular processes in the body, to diagnose disease and make patient management decisions (1,2). The use of unsealed artificial radionuclides for medical purposes in humans can be traced back to the experimental use of $^{24}$Na-sodium chloride by Hamilton and Stone in 1936 (3), closely followed by administration of $^{32}$P-phosphate by John Lawrence in 1937–1939 (3) to patients with hematological diseases and $^{131}$I-iodide by Hamilton to patients with thyroid disease. Later $^{131}$I-iodide became established for treating thyroid disease. However, the use of radioisotopes for diagnostic medical imaging did not become routine in hospitals until the 1970s, following the introduction of the first commercial gamma camera in 1968 (4) (and later, its evolution into single photon emission computed tomography (SPECT)). Equally important in the rise of nuclear medicine was the $^{99m}$Tc generator, first used for medical purposes in 1961 (4) and
firmly established in routine practice by the 1970s. This simple device solved the problem of world-wide distribution of short half-life radionuclides and enabled hospitals, for the first time, to have daily access to a radionuclide with excellent imaging properties: a gamma emission spectrum with a single photopeak at 140 KeV, offering a good balance between low attenuation and efficient detection outside the body, low radiation dose to patients because of its lack of particulate emissions and short half-life (6 h), and versatile chemistry. By means of the generator, $^{99}$Mo, a nuclear reactor-derived beta-emitting radionuclide with a half-life of 60 h, could be transported to hospitals around the world in the form of molybdate ($\text{MoO}_4^{2-}$) ions bound to a solid phase (alumina). As the $^{99}$Mo decays to $^{99m}$Tc, the daughter product pertechnetate ($^{99m}$Tc$\text{O}_4^{-}$) can be eluted from the solid phase with sterile physiological saline and converted into a variety of different tracers for a range of diagnostic applications. The range of $^{99m}$Tc-radiolabeled chemical entities that quickly became accessible following the availability of the generator, combined with the ease of their synthesis on the hospital site by means of simple kits (vials containing the chemical ingredients needed to convert the $^{99m}$Tc from the “raw” pertechnetate into the required chemical form) firmly established $^{99m}$Tc as the most widely used radionuclide in medicine, and brought a focus on metallic radionuclides as a field in which metallochemistry could find valuable biomedical applications. Early tracers ranged from simple lipophilic complexes for hepatobiliary imaging to simple anionic hydrophilic complexes for renal function imaging, and bisphosphonate complexes for skeletal imaging.

Although the concept of positron emission tomography (PET) evolved around the same time as gamma camera imaging, it did not develop from a research tool into a widely used clinical diagnostic tool until the 1990s. Its expansion was primarily driven by the introduction of the first PET tracer of wide utility in many diseases, the glucose analog $^{18}$F-fluorodeoxyglucose, used primarily for identifying and staging cancer. While PET has the advantage of better resolution and quantification than gamma camera and SPECT imaging, the short half-life of many of its tracers (e.g., only 110 min for $^{18}$F) demanded significant investment in infrastructure, requiring cyclotron facilities to be installed at locations within 2–4 h traveling distance of PET scanners. The availability of the new imaging modality spawned interest in developing a much wider variety of PET tracers, to enhance its versatility. This created not only applications for organic chemists to develop tracers based on small molecule metabolites and receptor ligands labeled with the positron emitters $^{18}$F and $^{11}$C, but also opportunities for inorganic chemists.
to develop novel positron-emitting metallic radionuclides (1) and to use inorganic chemistry in novel ways to incorporate $^{18}\text{F}$ into useful PET imaging agents (5). In this progress report, we review the use of inorganic chemistry to develop radionuclide imaging from gamma camera imaging and SPECT (with $^{99m}\text{Tc}$ as the main radionuclide) toward PET (with gallium, copper, zirconium, and fluorine isotopes) and multimodality imaging.

2. TECHNETIUM-99M: SMALL COMPLEXES

2.1 From Serendipity to Design

The $^{99m}\text{Tc}$-labeled radiopharmaceuticals that came into widespread daily use in the 1970s were largely a product of early biological experiments in which complexes were made with “off the shelf” chelating ligands selected in the absence of detailed knowledge of the coordination chemistry of technetium (1). In most cases their structures remain unknown even now, and their approval in today’s regulatory climate would have been most unlikely. Nevertheless, they were extremely successful and medically useful. Examples (Figure 1) include DTPA (1), meso-DMSA (2), bisphosphonates (3), HIDA (4), and various colloids (predating “nanotechnology” by decades) and macro-aggregates made from albumin.

In the 1980s and 1990s, as understanding of the coordination chemistry of technetium grew (6), a new generation of complexes found their way into nuclear medicine, with a greater element of chemical design in their development and with well-defined structures but still with simple, kit-based synthesis. It became clear that because of the greater covalent character and greater pi-bonding tendency (both ligand-to-metal and metal-to-ligand, depending on oxidation state) shown by technetium compared to other metals discussed in this chapter, polydentate chelators were not always necessary and bidentate and even monodentate ligands would provide sufficient \textit{in vivo} kinetic stability for many purposes (1). The concept of technetium “cores” emerged—that is, a set of well-defined stable complex building

![Figure 1](image_url) Ligands used in first-generation $^{99m}\text{Tc}$ radiopharmaceuticals. The structures of the technetium complexes are not shown because in many cases they remain unknown.
blocks adapted to the coordination preferences of technetium (and in most cases, importantly, to rhenium too) that could be elaborated and functionalized for different purposes. Examples (Figure 2) include the TcO\(_3^+\) with mixed tetradentate sulfur and nitrogen chelating ligands such as the MAG3 complex (5) for renal function imaging, “pentavalent” DMSA complex (6) for medullary thyroid carcinoma and bone disease (7–15), HMPAO complex for cerebral perfusion imaging and cell labeling (7), Tc(isonitrile)\(_6^+\) (8, e.g., sestamibi for myocardial perfusion imaging), TcO\(_2^+\) (with tetraamine 9 or diphosphine 10 chelating ligands), Tc(CO)\(_3^+\) (11), and TcN(dithiocarbamate)\(_2\) (12) (16–20). Some of these are discussed in more detail below.

## 2.2 Tc(I)tricarbonyl

The Tc(I) tricarbonyl core offers exceptional kinetic stability, especially when incorporated into complexes in which it is attached to targeting ligands by means of a bifunctional chelator designed specifically to accommodate the low oxidation state technetium (i.e., tridentate and able to coordinate in a facial geometry (11, Figure 2)) (21). A number of ligands have been devised for the latter approach, including the dipyridylamino (dpa) group in which the chelator is incorporated into an amino acid ready for incorporation into a peptide using solid-phase synthesis, (22) as described

![Figure 2](image-url) Established “core complexes” of technetium with well-defined structure and high stability, used in current approaches to the design of \(^{99m}\)Tc radiopharmaceuticals. X represents a linker group for bioconjugation.
below for hynic. The dpa chelator has been used to link \( ^{99m}\text{Tc}(\text{CO})_3^+ \) not only to biomolecules but also to small molecule targeting moieties such as bisphosphonate derivatives (13, Figure 3) (16–20). This offers a potential advantage over conventional technetium bisphosphonate complexes, because the bisphosphonate group is free and available to fulfill its biological function (e.g., binding to bone mineral) rather than being partially protected by binding to the technetium, and because the structure of the complex is known, homogeneous, well-defined and stable, in contrast to the mixtures of unstable complexes obtained with conventional bisphosphonates in \( ^{99m}\text{Tc} \)-labeling kits. The result is higher and more prolonged incorporation into regions of high bone turnover, despite their slower kinetics (19,20). These complexes can also be used for imaging soft tissue and vascular calcification (16) and for linking \( ^{99m}\text{Tc} \) to various inorganic nanoparticulate materials (such as iron oxides) for combined modality imaging (17,18,23).

### 2.3 Tc(V) Complexes

There is an extensive literature, which is beyond the scope of this chapter, describing Tc(V) mono-oxo-complexes with linear tetradentate chelators containing a combination of sulfur and nitrogen ligands: N4 (24,25), SN3 (5, Figure 2), and S2N2 (where S is thiolate or thioether (26) and N is an uncharged amine or a deprotonated amine or amide) (27). In addition, the Tc(V)-oxo-bis(dithiolate) core, best known in the form of the

![Figure 3](image)

**Figure 3** Left: Bifunctional complexes of \( ^{99m}\text{Tc} \) linked to bisphosphonate groups. Right: SPECT images showing the biodistribution of (left to right, respectively) conventional \( ^{99m}\text{Tc} \) bisphosphonate (3) complex of unknown structure, and bifunctional complexes 14 and 13, in mice with systemic arterial and soft tissue calcification. As well as skeletal uptake typical of bisphosphonate complexes, strong uptake is seen in the calcified mesenteric arteries (arrows) and other soft tissues.
dimercaptosuccinic acid complex (6, Figure 2) (8,9), is notable for its excellent in vivo stability (11) well-defined structure and ease of synthesis under mild conditions directly from pertechnetate. This complex is useful clinically for imaging of medullary thyroid carcinoma (28) and metastatic bone disease (11,12) and other tumors. It also has potential for conjugation to targeting ligands by virtue of its carboxyl groups. The synthesis of the corresponding dianhydride of this complex (15) provides a simple route to functionalization by reaction with amines linked to targeting groups such as phosphonate (29), imidazole (30), and biomolecules (15), while esterification of the complex offers further opportunity for biological targeting. Despite its advantages of ease of synthesis, well-defined structure and biological stability, it suffers from the limitation that, having two separate bidentate ligands, it forms three isomers (syn-endo, as shown in Figure 2, syn-exo, and anti), making this system less attractive from a regulatory standpoint. Once one or more of the carboxylate groups is conjugated, the number of isomers increases further. In the case of the rhenium analog, some progress in improving the preference for a single isomer (syn-endo) (15) has been made by judicious choice of synthesis conditions and reducing agent, but this remains a challenge for further development in the case of $^{99m}$Tc.

The Tc(V)-nitrido core, which is also well-characterized structurally in the form of bis(dithiocarbamate) complexes, has become recognized recently as a means of synthesizing structurally well-defined complexes (31) such as the myocardial perfusion imaging agent $^{99m}$Tc-NOET (12, Figure 2) (32), taking advantage of its ability to act as a center for assembly of two targeting ligands (such as antibiotics, bisphosphonates (16)), and thus offering a platform for synthesis of “divalent” targeting agents. Although the divalent bisphosphonate derivatives (14, Figure 3) provide excellent SPECT images of bone remodeling and soft tissue and arterial calcification (16), the extent to which their divalent nature is advantageous for this class of complexes is not yet clear, although divalency has been established as a successful approach to enhancing target affinity in other bioconjugate systems (33). The high symmetry of these complexes, and the fluxionality of the coordination sphere, means that the isomerism that besets the dimercaptosuccinic acid system may be less problematic in the dithiocarbamate ligand system. However, it does not have the advantage of being easily synthesized in a single step from pertechnetate: the current method requires synthesis of the Tc(V) nitride core with intermediate ligands prior to a ligand substitution step. This system will have much greater promise if a single-step synthesis can be devised.
2.4 Bioconjugates: A New Challenge

Following the development of well-characterized small complexes based on stable technetium core complexes, the design of molecular imaging agents has shifted again, toward targeting specific receptors and transporters, by incorporating $^{99m}$Tc into biomolecules such as peptides and proteins (1). The “technetium core” principle has been important in this endeavor. Although the synthesis of $^{99m}$Tc-radiopharmaceuticals as simply as possible using minimal equipment remains an important aspiration to increase their likelihood of clinical application, the development of simple labeling kits for the new generation of biomolecular tracers has had limited success.

It is outside the scope of this review to catalogue the various approaches to synthesis of $^{99m}$Tc bioconjugates; instead it is appropriate to identify the challenges that remain in achieving the “one-step” kit-based ideal. The chemistry is complex, as most approaches entail both exchange of ligands and reduction of Tc(VII) in order to convert pertechnetate into the bioconjugate, and the process must proceed quickly, using nontoxic reagents, under mild aqueous conditions, in almost quantitative yield to avoid the need for purification which introduces undesirable additional steps. The closest approach to this ideal is represented by the examples of a bifunctional chelator, hydrazinonicotinamide (hynic) (34) and the tricarbonyl (Tc(CO)$_3^+$) complexes.

2.5 Bioconjugation with Hynic

Hynic (15, Figure 4) can be conjugated to targeting molecules via its carboxyl group, and the hydrazinopyridine group offers a potentially bidentate coordination of technetium with the coordination sphere completed by a range of other monodentate and chelating ligands. Hynic is widely used to label proteins and peptides with $^{99m}$Tc, and the bioconjugation is often depicted as incorporating a monodentate coordination to technetium via the hydrazine functionality. However, comparison of the coordination behavior of relatives of hynic 16–20 shown in Figure 4 and with phenylhydrazine analogs, X-ray crystal structures of model complexes and mass spectrometry of the technetium complexes (35,36) using the long-lived isotope $^{99}$Tc suggests otherwise: bidentate coordination, via both the terminal nitrogen of the hydrazine moiety and the pyridine nitrogen, is more likely (21, Figure 4), with technetium formally in oxidation state V and free of oxo, hydroxo, and chloride ligands. The kinetic stability of the Tc-hynic coordination is adequate to survive in vivo conditions. The kinetics of
radio-labeling of hynic conjugates, using raw pertechnetate and with stannous chloride as a reducing agent, can be excellent and conducive to the ideal of kit-based labeling at high specific activity and without need for post-labeling purification. However, this efficiency varies greatly among different coligands used to complete the coordination sphere of the technetium atom. Reduction of pertechnetate by stannous chloride in the presence of tricine provides excellent labeling efficiency, but the ternary complex formed has multiple coordination isomers with tricine coordinated in different modes, and is vulnerable to ligand exchange under in vivo conditions, including the possibility that histidine side chains near the hynic-containing residue contribute to the technetium coordination sphere (36,37). Ethylenediaminediacetic acid (edda) does not create ideal labeling conditions when used in this way but provides greater stability and fewer isomers (21, Figure 4) (37). The advantages of both can be gained by performing the initial labeling using tricine and then substituting edda, but this creates an additional step and does not completely solve the problem of isomerism. The ideal kinetics created by tricine probably arise because the intermediate Tc(V)-oxo-tricine complex formed upon reduction of pertechnetate in the

---

**Figure 4** Hydrazinonicotinamide (hynic) derivatives for synthesis of bioconjugates of ⁹⁹ᵐTc. Structure 15 is the prototypical hynic, while 16–20 are variants synthesized for comparison. Structure 21 represents a likely (bidentate) coordination mode of the hynic, with the coordination sphere completed by ethylenediaminediacetic acid (edda).
presence of tricine is, fortuitously, close to optimal for reaction with hyenic in a way that edda and other ligands cannot match. Since mechanistic details of this multistep redox/ligand substitution reaction are unknown and inevitably very complex, it is hard to predict what types of ligands will provide the desired combination of fast kinetics of complexation, high resistance to transchelation in vivo, and formation of a single isomer. The combination of hyenic and tricine provides a starting point for this search; a number of alternative coligands based on phosphines and pyridine derivatives have been evaluated but an optimal design has not yet been reached (34). Nevertheless, synthetic refinements to facilitate easy use of hyenic for 99mTc labeling of peptides and proteins have been developed, including derivatives with the carboxyl linker group in different positions (Figure 4) (38), hyenic-amino acid derivatives to incorporate hyenic into peptides site-specifically using conventional solid-phase synthesis (39), conjugates with maleimide and other linkers to increase versatility of linkage to proteins, and protected forms of hyenic (40,41) to prevent cross reaction of the reactive hydrazine moiety with proteins and peptides. The protected forms include a trifluoroacetyl derivative in which the complex formation with technetium catalyzes the deprotection (42), ensuring that free reactive hydrazine groups are not exposed at any point pre or postlabeling.

2.6 Bioconjugation with Other Bifunctional Chelators

Some of the Tc(V) cores with nitrogen and sulfur ligands described above have demonstrated potential as bifunctional chelators for biomolecule labeling. The most readily accessible (by virtue of the commercial availability of kits for MAG3 labeling) is 5 (Figure 2) (43), which can be linked to proteins and peptides by activation of its uncoordinated carboxyl group. The DMSA anhydride complex of rhenium (15) mentioned above suggests a possible route to developing analogous technetium chemistry as a biomolecule labeling system. A novel approach in which two DMSA moieties are bridged by a linker to produce a tetridentate bifunctional chelator has the potential to simplify the use of the DMSA system for bioconjugation (44).

2.7 Bioconjugation with the “Tricarbonyl Core” Tc(CO)₃⁺

The Tc(CO)₃⁺ core is an extremely versatile synthon that can be incorporated into targeting agents not only in the form of small molecules, as described above, but also as a direct attachment to proteins via polyhistidine sequences (His-tags, sequences of typically six histidine residues), offering
excellent kinetic stability of the final labeled product (45). Because many bioengineered proteins incorporate His-tags, this is particularly convenient and provides a degree of site specificity because the $^{99m}$Tc becomes attached much more efficiently to the His-tag than to other amino acid sequences (46). Until recently, this site specificity was assumed rather than proven, but analysis by tryptic digest and electrospray mass spectrometry has shown that although a single histidine residue is sufficient to incorporate the $^{99m}$Tc, the labeling is indeed selective for the His-tag (47, 48). The structural details of the facial coordination of the $^{99m}$Tc(CO)$_3^+$ fragment by the protein, including the identity of the donor atoms and the number of histidine side chains involved, remain unknown, and it is likely that isomers are formed leading to inhomogeneity of structure. There are certainly variations in labeling efficiency between proteins: some can be labeled efficiently at low concentration while others require purification even after labeling at relatively high concentration, indicating that the identity of the amino acids in the vicinity of the His-tag, and perhaps the overall protein structure, influence labeling efficiency. In particular, incorporation of a nearby cysteine residue (47–49), or modification of the protein to incorporate a thiol prosthetic group (50), improved the labeling efficiency under mild conditions. To help identify the factors affecting labeling efficiency, and to engineer an optimal His-tag design that would ensure efficient labeling of any protein containing the sequence, a high-throughput screen approach was adopted in which various arrangements of His-tag sequences and accompanying amino acids were screened for $^{99m}$Tc labeling on a solid-supported two-dimensional array. This screen showed that labeling efficiency could be enhanced by an order of magnitude, under mild conditions (room temperature, neutral pH, very low protein concentration) by including positively charged amino acids close to the His-tag, if the labeling is performed in the conventional phosphate buffer (Figure 5) (51, 52). This raises the possibility of designing targeting proteins not only to bind to their target receptor but also to ensure the simplest and most efficient labeling and avoid the need for purification steps.

Despite these advances, the $^{99m}$Tc(CO)$_3^+$ fragment remains suboptimal for routine use in hospitals because it is necessarily a two-step process—that the $^{99m}$Tc(CO)$_3^+$ fragment has to be synthesized (and sometimes purified) and then it has to be incubated with the protein. Although conditions have been optimized to make the labeling as simple and efficient as possible (49), the challenge to achieve single-site labeling in a single step under mild conditions to give a homogeneous, high specific-activity product remains unmet.
2.8 Bioconjugation by Direct Labeling Via Cysteine

A well-established route to incorporating $^{99m}$Tc into monoclonal antibodies is reduction of interchain disulfide (cystine) linkages followed by insertion of prereduced $^{99m}$Tc by ligand substitution, to take advantage of the affinity of $^{99m}$Tc for thiolate ligands. This is a simple and reliable method, with wide utility and versatility, but the labeled antibody has limited in vivo stability.

Figure 5 Chelators and building blocks established and under development for incorporation of $^{68}$Ga into radiopharmaceuticals. Commonly used names for the chelating groups are as follows: DOTA (22), NOTA (23), TRAP (24), desferrioxamine (DFO, 25), DEDPA (26), HBED-CC (27), Deferiprone (28), and THP (29–32).
compared to antibodies labeled with (for example) $^{111}$In via well-designed chelators such as DTPA and DOTA derivatives. There have been a number of attempts to use a similar approach to label smaller peptides containing cysteine loops; however, the labeled products are usually poorly characterized with unknown structures. The only attempts to define structurally the complexes formed (using electrospray mass spectrometry) have entailed use of water-soluble phosphines as the reducing agent for the disulfide bond, and have shown mixtures of species with poor stability, incorporating phosphine as well as thiolate in the coordination sphere, and $^{99m}$Tc in oxidation state III (53). The lack of structural control makes this method quite unsuitable for labeling of peptides and smaller proteins.

2.9 Rhenium Analogs

The potential importance of radionuclide therapy with beta-emitting isotopes $^{186}$Re (half-life 90 h, $\beta^-$, $\gamma$) and $^{188}$Re (half-life 17 h, $\beta^-$, $\gamma$ (54)) makes the periodic relationship between rhenium and technetium of great interest. The early chelating systems used before the recognition of the important stable technetium cores were not readily amenable to the inference of structural and biological parallel between technetium and rhenium, and many attempts to recreate $^{186/188}$Re-labeled complexes of this type have been unsuccessful (notably, for example, the rhenium and technetium complexes with coordinated bisphosphonate ligands have completely different biological behavior and stability (19,20,27,55)). However, when the stable core systems are used there is much greater parallel between rhenium and technetium, and much of the chemistry can be applicable to both metals, albeit often with adjustments to the labeling conditions to take into account the typically reduced reactivity, and reduced tendency toward reduction to lower oxidation states of rhenium compared to technetium. The M(CO)$_3^+$ systems show close structural analogy, as demonstrated by the dpa-bisphosphonate conjugate complexes (19,20) and the labeling of proteins with his-tags; the preferred his-tag-based amino acid sequences identified as most efficient for $^{99m}$Tc were also optimal for $^{188}$Re (52). The pentavalent $^{99m}$Tc and $^{188}$Re dimercaptosuccinic acid complexes also show identical structure (7–10) and (human) biological (13,14) behavior, as do the dithiocarbamate-bisphosphonate conjugates (16).

2.10 Summary: Challenges in Tc-$^{99m}$Tc Chemistry

The early development of $^{99m}$Tc radiopharmaceuticals was characterized by very simple preparative methods that disguised extremely complex
coordination chemistry. As technetium coordination chemistry became better understood, more stable and well-characterized complexes entered the clinical arena, with labeling methodologies remaining relatively simple. In the age of molecular imaging with bioconjugates (proteins, peptides, etc.), however, the methodology for radio-labeling has become more complex, which has hampered the widespread clinical use of labeled biomolecules. The chemistry of technetium is among the most complex of any element and the challenge to produce labeled bioconjugates with homogeneous structure, under mild conditions, in a single step, at low concentration/high specific activity is a goal that has not been met and deserves renewed effort. The recent shortages of $^{99}$Mo and hence $^{99m}$Tc, resulting from planned and unplanned downtime of nuclear reactors, has highlighted the global fragility of $^{99m}$Tc supply (56). The current international effort to plan new reactors, and develop new generator and elution designs to cope with lower specific-activity $^{99}$Mo (57) and alternative cyclotron-based means of production, testifies to the future continued importance of $^{99m}$Tc and encourages renewed efforts to develop technetium chemistry to achieve these goals.

3. THE TRANSITION TOWARD PET

3.1 The Need for Metallic Positron Emitters

Despite the clinical success and wide availability of gamma camera and SPECT imaging, and its advantages of relatively low cost and capability for imaging two or more isotopes simultaneously, the superior resolution and quantification of PET has made it increasingly more attractive even for applications that do not require organic small molecules like $^{18}$F-FDG. This has created opportunities for new chemistry to incorporate positron-emitting metallic radionuclides into radiopharmaceuticals. Foremost among these are $^{68}$Ga, $^{89}$Zr, and the copper isotopes $^{60/61/62/64}$Cu.


In many ways $^{68}$Ga (half-life 68 min) is emerging as “the new technetium,” i.e., a short half-life metallic radionuclide produced from a generator and easily introduced into a variety of molecules and biomolecules, but for PET instead of single photon imaging. It is produced on the hospital site by decay of germanium-68 (half-life 271 days) via the $^{68}$Ge/$^{68}$Ga generator (58). The decay of $^{68}$Ga produces a high yield of positrons and the Ga$^{3+}$
eluted is readily chelated with a variety of chelating agents (59) with good kinetic stability. Despite growing clinical use in recent years, especially in Europe, only in 2014 was the first commercial generator given marketing authorization for clinical use. This development has led to rapid expansion of its use. Its chemistry is much simpler than that of technetium, and there is only one relevant oxidation state (III). Nevertheless, the chelating agents used to couple it to biomolecules explored to date (22–27, Figure 5) have not been conducive to simple application in hospitals with limited radiochemistry facilities, requiring multiple operations including heating, use of low pH and purification steps. A genuinely single-step, kit-based labeling procedure that is functional at room temperature, moderate pH and very low concentration, affording a complex with good in vivo stability, would greatly increase its attractiveness and accessibility to more hospitals and patients. The current generation of chelating agents, mostly based on macrocyclic polyaminocarboxylate designs (Figure 5), meets some but not all of these requirements. Considerable effort has been focused recently on developing new chelators to overcome these problems. Much of the recent work has been summarized in an excellent recent review and is beyond the scope of this chapter (59).

In our laboratory, the approach to meeting these needs is to move away from macrocyclic ligands, and to exploit the similarity in coordination behavior of Ga$^{3+}$ with that of Fe$^{3+}$. This has led us to the design of tripodal tris(hydroxypyridinone) (THP) ligands (60) that incorporate iron-chelating side arms based on the successful iron-chelating drug Deferiprone (28, Figure 5) (61). The resulting chelating systems 29–32 form gallium complexes very rapidly at very low concentration, room temperature and neutral pH; only a single complex species was detected by HPLC, with a 1:1 stoichiometry as determined by electrospray mass spectrometry. The $^{68}$Ga complex of 29 has a very high association constant ($\log K = 29.1$ (62)) and excellent in vivo stability, and thus meets the requirements listed above more completely than other ligand designs recently reported (59). Direct comparison between chelators was investigated by progressively reducing the chelator concentration until labeling efficiencies began to fall below 95%, based on the premise that any chelator will efficiently complex the metal if its concentration is high enough; the best ligands will therefore retain efficiency at the lowest concentrations. With this approach, we showed that THP-Ac (29, Figure 5) outperformed established $^{68}$Ga chelators DOTA, NOTA, and HBED–CC even when each of these ligands was labeled under its respective optimal conditions (heat and low pH for DOTA,
low pH for NOTA, and HBED) and longer incubation, while THP-Ac was used at room temperature and close to neutral pH after 1–5 mins of incubation (60). The positioning of the linker group at the center of the tripod ensures that the coordination properties are not greatly affected by attaching the chelator to biomolecules. Versions of THP with maleimide (30) (60) (for linkage to thiol groups), amine (63,64) (for linkage to carboxylate groups, for example) and isothiocyanate linkers (31,32, Figure 5) (63,64), have been synthesized and used to prepare labeled antibodies (65–67), and smaller proteins and peptides (64). In vivo studies with several of these new radiopharmaceuticals in animal cancer models have shown excellent in vivo stability and tumor imaging properties (e.g., 33, Figure 6) (60,64).

The application of gallium chelators may not be restricted to PET imaging. The gamma-emitting isotope $^{67}$Ga has been used for many years in the clinic. In addition, its abundant and relatively high-energy Auger electron emissions have a range of track lengths commensurate with the dimensions of a cell (compared to the majority of Auger electron-emitters whose electrons have ranges in the order of nanometers). This offers the possibility of radionuclide therapy of cancer, at least in theory. This has yet to be

![Figure 6](image_url)  
**Figure 6** Structure of a conjugate of a THP chelator with a ligand that binds to the prostate-specific membrane antigen (PSMA), and nanoPET/CT images showing specific tumor targeting (arrow) in a mouse model of PSMA-expressing prostate cancer.
demonstrated successfully in vivo (68) but in vitro data indicate that intracellular $^{67}$Ga is at least as toxic on a per-decay basis as $^{111}$In (69), which has been clinically evaluated for radionuclide therapy (70). If this potential can be realized, the “theranostic” pair combining $^{68}$Ga PET with $^{67}$Ga therapy would have significant clinical application for both targeted detection and treatment of tumors.

3.3 Zirconium-89: “The New Indium-111”—ImmunoPET and Cell Tracking

Although short half-life radionuclides are preferred where possible in order to keep radiation doses to patients as low as possible, in many applications the localization and clearance processes are slow, and long periods between injection of the tracer and imaging are required to develop adequate target-to-background ratio. In these instances, longer half-life tracers are needed. In single photon imaging this is conventionally achieved with $^{111}$In, which can be attached to slow-localizing molecules like monoclonal antibodies (71) using bifunctional chelators, usually DTPA (72–74) (Figure 1) and DOTA (Figure 5) derivatives. With the increasing availability of PET, a longer half-life positron emitter has inevitably emerged as the PET analog of $^{111}$In: zirconium-89. The Zr$^{4+}$ ion is not effectively chelated by conventional chelators such as DTPA, DOTA, etc., that have found use with indium and other tricationic metals; indeed, very little work has been done to optimize ligand design for Zr$^{4+}$. Somewhat fortuitously, the siderophore desferrioxamine B (DFO, 25, Figure 5) has proved to be remarkably effective, despite being only hexadentate (whereas Zr$^{4+}$ typically is eight-coordinate). PET with $^{89}$Zr has now been used to follow the biodistribution and targeting of a number of antibodies in animal models and humans using the DFO method (75). Although evidence of significant instability of the zirconium-DFO complex in vivo is not conclusive even over several days, several groups are working to devise new ligand systems to optimize labeling efficiency and stability. The most popular approach is based on siderophore–like ligands but extended from hexadentate to octadentate (76). We have evaluated the THP ligands described above (30) for $^{89}$Zr$^{4+}$ chelation, and although in vitro their labeling properties and affinity constants are superior to those of DFO in vitro, the in vivo stability of the THP complex (attached to a monoclonal antibody via the maleimide linker) was markedly inferior to the DFO conjugates over a period of several days (77).

A second area of application of longer lived radionuclides is that they can be incorporated into living cells to track their migration in vivo by imaging.
This has been routinely used clinically for imaging the migration of leukocytes which have been isolated from the patients’ peripheral blood, radiolabeled (conventionally with $^{111}\text{In}$ or $^{99m}\text{Tc}$) and reinjected in order to locate hidden sites of infection and inflammation using a gamma camera. The most widely used cell labeling method utilizes lipophilic metastable six-coordinate complexes of $^{111}\text{In}^{3+}$ with three monobasic bidentate ligands, such as the tris(oxinate) (34, Figure 7) and the tris(tropolonate) complexes, which diffuse nonspecifically into cells by virtue of their lipophilicity, but dissociate inside cells in the presence of competing ligands. A PET analog of this imaging method would offer the necessary improvements in sensitivity, quantification, and resolution needed to address new challenges in cell tracking, such as clinical trials of cellular therapies and the development of methods to isolate specific subtypes of endogenous leukocytes (80,83). $^{89}\text{Zr}$ has the potential to meet this need.

Figure 7 Left: Complexes of $^{111}\text{In}$ (34) and $^{89}\text{Zr}$ (35) with 8-hydroxyquinolinate (oxinate); right: time-dependent imaging of myeloma cell migration after intravenous injection of cells labeled with $^{111}\text{In}$-oxinate and $^{89}\text{Zr}$-oxinate (SPECT/CT and PET/CT images, respectively). Both show broadly similar distribution—initial retention in lungs followed by migration to liver, spleen, and bone marrow, but the lower uptake of $^{89}\text{Zr}$ in kidneys compared to $^{111}\text{In}$ in the later images is an indication that the $^{89}\text{Zr}$ shows less efflux from the labeled cells.
Despite its preferred oxidation state of IV rather than III, zirconium shows parallel behavior to indium and can form eight-coordinate complexes with four such ligands. Oxine, tropolone, and other monobasic bidentate ligands have been evaluated for cell labeling, and so far the oxinate complex (35, Figure 7) has emerged as the lead candidate (84). The $^{89}\text{Zr}$ tetrakis(oxinate) complex is readily synthesized and labels cells efficiently and with prolonged stability, succeeding where other PET tracers evaluated for cell tracking (e.g., copper isotopes, see below) have failed. Not only does it have the advantage of PET imaging (compared to gamma imaging), but the cells also show more stable labeling (i.e., less loss of radioactivity over a period of days in vivo) and better cell survival than cells labeled with $^{111}\text{In}$ (85). A variety of human cell types and cultured cell lines have now been labeled by this method and it appears to be generally applicable as the first stable, robust method for cell labeling with a long half-life positron emitter. Many clinical applications in detection of inflammation, infection and early evaluation of cellular therapies are envisaged.

4. Copper: Exploiting Redox Chemistry

4.1 Copper Isotopes and Bioconjugates

Copper has several positron-emitting radionuclides with a range of half-lives suited to different applications. The most generally useful is the cyclotron-produced isotope $^{64}\text{Cu}$, with a half-life of 12.7 h. It has a complex decay profile, with three principal decay modes: positron (18%), electron capture (43%, accompanied by Auger electron emission) and beta emission (39%). All these offer potential for radionuclide therapy and hence $^{64}\text{Cu}$ has “theranostic” potential, although the therapeutic aspect has not been exploited clinically. The low energy of the positron (0.65 MeV) allows high-resolution PET imaging, and its relatively long half-life makes it useful for preclinical laboratory research as well as for clinical applications that require prolonged scanning (>24 h). For applications not requiring delayed imaging (e.g., small peptides, proteins, and complexes), shorter half-life isotopes are preferred and $^{60}\text{Cu}$ (cyclotron produced, half-life 20 min), $^{61}\text{Cu}$ (cyclotron-produced, half-life 3.3 h), and $^{62}\text{Cu}$ (half-life 9 min, produced from the $^{62}\text{Zn}/^{62}\text{Cu}$ generator) are suitable. The radiochemistry and application of copper isotopes have been reviewed many times, but still the most comprehensive review available (86), published in 1996, is now very much out of date and needs a thorough update.
Neither of the two preferred oxidation states, Cu(I) or Cu(II), offer great kinetic inertness. Cu(I), as a d^{10} ion, is particularly vulnerable to ligand exchange and has been very little used in radiopharmaceuticals, although preliminary work using Cu(I) bis(diphosphine) complexes has shown that the synthesis could be sufficiently rapid and efficient for use with the very short half-life isotope ^{62}\text{Cu} \,(87,88). Diphosphine ligands 36–40 (Figure 8) have been used to generate lipophilic cationic complexes Cu(diphosphine)_{2}^{+}, some of which served as substrates for the P-glycoprotein (MDR-1) and

![Chemical Structures](image)

**Figure 8** Chelating agents for copper radionuclides, with copper in oxidation state I (36–42) and II (43–47).
could therefore be used for PET imaging of multidrug resistance in tumors (89). The diphosphine ligands could be derivatized as anhydride (41) and carboxylic acid (42) derivatives (Figure 8) and thus serve as bifunctional chelators, providing sufficient biological stability to be useful for labeling biomolecules (88). Where labeling of biomolecules with long term in vivo stability is necessary, Cu(II) is preferred and stability has to be enforced by polydentate macrocyclic amine and aminocarboxylate ligands. Even macrocycle-based ligands such as cyclam (43), TETA (44), DOTA (22, Figure 5), and NOTA (23, Figure 5) are perceived as inadequate to enforce the in vivo stability required for some applications, and cross-bridged macrocycles and bicyclic ligands such as cross-bridged forms of TETA and DOTA (e.g., 45) have been introduced to overcome this problem (Figure 8). Cross-bridged derivatives indeed offer improved in vivo stability, but at the expense of slower complex formation, requiring harsher labeling conditions (e.g., heat) that may be incompatible with some biomolecules. The sarcophagine-based ligands that are of key historical significance in the development of macrocyclic chemistry have been adapted by incorporation of linkers for use as copper bifunctional chelators for biomolecule labeling (46, Figure 8), including “divalent” receptor-targeting molecules with peptides linked at both ends of the cage (47, Figure 8) (90); they offer an appropriate balance of mild labeling conditions combined with excellent in vivo stability, and perform well in head-to-head in vivo comparison with other candidate copper chelators (91).

4.2 Bioreductive Trapping—Imaging Blood Flow and Hypoxia

While other positron-emitting radiometals (e.g., 89Zr, above) may be more suitable for labeling biomolecules where in vivo kinetic stability is required, copper has a unique attribute that other radiometals do not: a simple, controllable redox chemistry that can be manipulated and exploited for molecular imaging purposes. The intracellular reduction of Cu(II) to Cu(I) is a biologically feasible process that leads to instability of chelate complexes and is believed to represent a major pathway for undesirable metal–ligand dissociation in copper bioconjugates. For other purposes, however, bioreduction offers a versatile and useful mechanism of trapping radiocopper within cells. This possibility was first recognized in the cellular trapping mechanism of the blood flow tracer CuPTSM (48, Figure 9) (92), a bis(thiosemicarbazone) (BTSC) complex labeled with 62Cu or 64Cu. Use of PET to quantitatively map blood flow requires a tracer that is trapped
in cells efficiently and indiscriminately so that the uptake of tracer in a tissue is dependent only on its delivery via blood and not on other tissue or cell characteristics. Bioreduction provides this mechanism for CuPTSM (93), which is believed to be as follows: the complex is a small, planar, lipophilic molecule that is able to readily diffuse through cell membranes to reach the intracellular milieu, where it encounters cellular reducing agents (the identity of which is unknown or the subject of debate) and is reduced to a Cu(I) species. This species rapidly dissociates, releasing the Cu(I) to become bound to intracellular macromolecules and thus trapped within the cell. In the case of CuPTSM the reduction and dissociation, and hence trapping, of copper is so rapid that it is almost independent of variations in cell metabolism between tissues and indeed is roughly proportional to blood flow.

A remarkable feature of the BTSC complexes is that their biological behavior can be exquisitely tuned by variation in alkylation at the diimine backbone and at the amino termini (Figure 9). Indeed, these two sites offer a degree of independent control of reduction potential and lipophilicity, respectively. The sequential replacement of the two backbone hydrogens of the “parent” CuGTS with alkyl groups lowers the Cu(II)/Cu(I) reduction potential in steps of roughly 60 mV per alkyl group (as measured by cyclic

**Figure 9** Bis(thiosemicarbazone) complexes of copper showing variations of structure for control of lipophilicity and control of hypoxia-selective and nonselective intracellular trapping.
voltammetry in DMSO solution) making the complexes progressively harder to reduce. Meanwhile, replacement of the hydrogens of the terminal amine groups by alkyl groups has relatively little effect on redox potential, but influences the lipophilicity and thereby cell permeability and pharmacokinetics (94–97). These features can even be varied and optimized by means of a combinatorial approach in which a mixture of several diketone and thiosemicarbazide components is reacted to create a library of BTSC ligands (98).

The structural, mechanistic, and electronic structure features of CuBTSM complexes, especially the role of the backbone alkyl groups, underlying these structure activity relationships have been investigated in some detail. Cyclic voltammetry showed that backbone alkyl groups not only shift the Cu(II)/Cu(I) reduction potential by ca. 60 mV per alkyl group, but also make the reduction process more reversible (i.e., delay the acid-catalyzed dissociation) (99); while reduction of CuATSM (50, Figure 9) was reversible in DMSO, it was rendered irreversible by addition of acetic acid. CuPTSM required less acid to make the reduction irreversible while reduction of CuGTSM (51) was so sensitive to protons that reversible electrochemistry could only be observed in scrupulously dried DMSO. Density functional calculations showed that the effect of the backbone methyl groups in lowering the Cu(II)/Cu(I) redox potential could be predicted from theory (99), and variation in calculated structures and HOMO/LUMO energy levels induced by varying either backbone alkylation or replacing sulfur donor atoms with selenium, matched experimental results (X-ray crystal structures, electronic spectroscopy, electron spin resonance (ESR) spectroscopy, cyclic voltammetry) very well (100). A series of X-ray crystal structures also demonstrated a subtle effect by which the steric effect of backbone alkyl groups was amplified to induce a significant shortening of the copper–sulfur bond lengths in the CuBTSC complexes (101). This shortening could be expected to increase electron donation by sulfur to copper. This too was predicted by the density functional calculations and may be an important contributor to the lower reduction potential.

Backbone alkylation makes reduction harder and delays dissociation post-reduction. When combined with the ability of the reduced species to be reoxidized to the Cu(II) BTSC complex by molecular oxygen, these effects create a potential mechanism for hypoxia-selective trapping of copper within the cell, and hence a means of PET imaging of hypoxic tissue—a valuable clinical tool because of the importance of hypoxia in many diseases,
especially in relation to radiotherapy of cancer. This potential has indeed been realized with the prototype hypoxia imaging complex CuATSM, which is related to CuPTSM by substitution of the hydrogen in the backbone by a methyl group, turning it from a blood flow imaging agent into a hypoxia imaging agent (102). The hypoxia selectivity of CuATSM has been experimentally confirmed both in cultured cells in vitro and in animal models. A rationale for the hypoxic selective trapping of copper with CuATSM, based on the physicochemical observations described above, is as follows (96,100): the complex enters cells and is subject to intracellular bioreduction as described above. Because of the lower redox potential, reduction may be slower and the complex may thus have more time to diffuse out of the cell—unless the environment is hypoxic, where a more reducing environment increases the likelihood of tracer reduction and dissociation even in complexes with low redox potential because of their backbone alkylation. This mechanism relies only on the low redox potential to create selectivity. An additional level of selectivity may arise from the additional reversibility of the reduction process endowed by the backbone alkyl groups; once reduced, the reduced species dissociates more slowly, allowing time for the complex to be reoxidized by molecular oxygen (it is known from chemical reactivity studies that the reduced species can be reoxidized by O₂ (99)) whereupon it can diffuse back out of the cell and be cleared; hence, dissociation and trapping only occurs if oxygen is limited.

⁶⁰CuATSM, ⁶²CuATSM, and ⁶⁴CuATSM have all been evaluated in clinical trials in cancer patients, and shown some promise for predicting the outcome of radiotherapy (103–106). ⁶⁴CuATSM has also been shown to be more toxic to hypoxic cells than to normoxic cells, simply by virtue of the increased uptake in hypoxic cells (107). However, not all of the preclinical and clinical evaluations of hypoxia imaging have produced encouraging results, and the principle of hypoxia selectivity of CuATSM in vivo remains subject to some discussion (106,108). Some studies indicate that CuATSM uptake is regulated primarily by hypoxia while others conclude that blood flow is the main determinant. It has also been suggested that the biodistribution of CuATSM may reflect the behavior of ionic copper rather than the intact CuATSM complex (108), although given the very different biodistribution of several different CuBTSC complexes (see above and below) this seems unlikely. An additional nonideal feature of CuATSM, which it appears to share with most other current hypoxia tracers, is that it is only trapped in cells suffering the most extreme hypoxia—when the
oxygen partial pressure in the medium is below 0.1 mm Hg (96)—whereas the partial pressure of most interest clinically (e.g., to predict tumor radiation sensitivity or impaired cardiac energetics) is much higher (ca. 20 mm Hg is the threshold below which cellular radio-sensitivity begins to drop substantially). This extremely low threshold suggests that only a very small subset of cells in a hypoxic region of tumor will be hypoxic enough to trap the tracer, and consequently the uptake will be much lower than optimal leading to images with limited clinical usefulness (109).

Given the clear indication from in vitro studies that CuBTSC complexes with two alkyl groups in the diimine backbone are selectively trapped in hypoxic cells, efforts to overcome these nonideal hypoxic targeting properties of CuATSM are warranted. Possible strategies are to investigate the mechanism of trapping to identify other potential features that may control tracer uptake, and to modify the pharmacokinetic properties of the system by varying tracer lipophilicity. As an approach toward both of these objectives we have adopted the Langendorff isolated perfused rat heart model, which offers the advantage of being an efficient flow-through intact organ preparation (with consequent major advantages over cell culture systems) without the complexity and lack of control associated with in vivo models. It is of course also directly relevant to imaging hypoxia in the myocardium, which is of interest but currently underdeveloped as a diagnostic technique in cardiology (110). This system, indeed, was used to demonstrate the hypoxia selectivity of CuATSM for the first time (102). It offers almost complete experimental control and monitoring of the oxygenation, flow rate, energy consumption, and contractile performance characteristics, while allowing monitoring of radiotracer trapping or washout with subsecond temporal resolution. It allows several tracers to be evaluated rapidly in sequence under varied conditions, for example, by switching the perfusion buffer from oxygenated to anoxic (or intermediate levels of oxygenation), and pharmacokinetics can be modeled (111). None of these are effectively achieved in cell suspension systems (112). Some examples of the tracer uptake profiles are shown in Figure 10. The system has been used to investigate three questions:

- Can features of tissue and cellular metabolism other than simple oxygenation (such as intracellular pH or thiol levels) influence copper retention after administration of CuATSM?
- Can complexes be found with improved pharmacokinetics (faster clearance from normoxic tissue) and hypoxic selectivity (higher uptake in hypoxic cells and/or lower uptake in normoxic cells)?
Can complexes be found that “switch on” cellular trapping at less extreme levels of hypoxia, more aligned with levels at which clinical symptoms and consequences occur? The first was addressed by pharmacological manipulation to increase intracellular glutathione levels significantly above normal, and to decrease them significantly below normal, in hearts to which CuATSM was then administered under normoxic and anoxic conditions. Neither hypoxic nor normoxic uptake was affected by these changes (113). Similarly, inducing acidosis did not affect the hypoxia dependence of copper trapping, despite suggestions based on the acid-dependence of dissociation of the reduced CuATSM species that acidosis might promote trapping. Thus, it was conclusively shown that neither increases in cellular reduced glutathione, nor decreases in cellular pH, are required to induce selective trapping of CuATSM in hypoxic cells; so far, no metabolic features other than oxygen concentration have been shown to influence tracer uptake directly.

Figure 10 Time-dependent uptake of radioactivity after injection of a bolus of $^{64}$Cu BTSC complexes into isolated Langendorff-perfused rat hearts at 10, 35, and 55 min after the start of perfusion. The y-axis represents radioactivity within the heart. White areas indicate periods of supply of oxygenated buffer while shaded areas indicate supply of anoxic buffer. CuPTSM shows a high level of trapping under oxygenated conditions and even higher (close to 100%) under anoxia. CuATSM on the other hand shows low (ca. 10%) trapping under normoxia increasing to ca. 80% after 25 min hypoxia. CuATS and CuCTS show more rapid transit through the heart than CuATSM, and a greater selectivity in binding to hypoxic compared to normoxic heart. CuATSE (54) also shows hypoxia selectivity but takes much longer to transit through the heart because of its increased lipophilicity. Unchelated copper(II) (CuCl$_2$) shows no uptake under either normoxia or hypoxia.

- Can complexes be found that “switch on” cellular trapping at less extreme levels of hypoxia, more aligned with levels at which clinical symptoms and consequences occur?
The second question addresses a problem with selectivity of CuATSM which can be seen by inspection of Figure 10. Although copper uptake in hypoxic hearts is several-fold higher than in normoxic hearts, there remains some significant residual uptake in normoxic hearts of about 10%. This provides a possible hypothesis to explain observations in several (not all) in vivo tumor model studies that CuATSM uptake reflects blood flow/perfusion rather than hypoxia. On the assumption that, in tumors, the most hypoxic cancer cells are likely to be those most distant from capillaries, to reach many of the hypoxic cells CuATSM molecules must traverse layers of oxygenated cells. The residual normoxic trapping evidenced in Figure 10 would mean that much of the tracer would never reach the distal hypoxic cells. In these circumstances, CuATSM becomes a rather inefficient flow tracer instead of a hypoxia tracer. This hypothesis suggests that a less lipophilic version of the tracer would be less likely to enter proximal normoxic cells en route to the distal hypoxic tumor cells, and also may be cleared from normoxic tissues more quickly by spending less time sequestered within membranes. A study examining the dependence of the tracer uptake profile in the heart on lipophilicity and reduction potential of the CuBTSC complexes showed that this reasoning has value in identifying improved hypoxia tracers: two alternative analogs with reduced lipophilicity (by removing methyl groups from the terminal amine position), CuATS (52) and CuCTS (53) (Figure 9), showed reduced trapping and faster clearance from normoxic hearts, and increased trapping in hypoxic hearts (i.e., both improved pharmacokinetics and improved hypoxia selectivity; Figure 10) (114). On the other hand, CuATSE (54, Figure 9) (115), which is hypoxia selective (having two backbone alkyl groups) but more lipophilic than CuATSM (having terminal ethyl instead of methyl groups) has a hypoxia-selective profile but achieves selectivity much more slowly because of delayed clearance (Figure 10). This further exemplifies the value of controlling lipophilicity to improve biodistribution in different organ systems and disease states, as previously demonstrated by the fact that CuATSM crosses the blood brain barrier while the less lipophilic CuATS does not (116). This study also confirmed that complexes with fewer than two alkyl groups in the diimine backbone (CuPTSM) show uptake that is almost independent of oxygenation. The two improved hypoxia-selective tracers CuATS and CuCTS are now being evaluated in vivo as hypoxia imaging agents.

To address the third question, of identifying BTSC complexes potentially capable of targeting clinically relevant degrees of chronic cardiac ischemia, we performed a series of hypoxic buffer titrations in Langendorff hearts...
to identify the threshold at which contractile function and cardiac energetics became compromised, but long-term cardiac survival would still have been likely. To date most studies had only evaluated tracer retention in totally hypoxic/ischemic hearts, which while useful, are of limited pathophysiological relevance. Using $^{31}$P NMR spectroscopy, we determined that at 30% buffer oxygen saturation, cardiac phosphocreatine levels were compromised, but crucially, ATP levels were maintained. Cardiac contractility was compromised, lactate levels were elevated but not maximal (representative of residual mitochondrial reserve), and HIF1α levels were elevated—all consistent with energetic profiles characterizing chronically diseased myocardium clinically. When we then evaluated our tracer candidates under these conditions, CuCTS uniquely began to be taken up as pO$_2$ reached this 30% oxygen saturation threshold, significantly sooner than any of the other tracers that we examined, including CuATSM (117). Encouragingly, in vivo studies in rats showed that CuCTS is not significantly taken up in the normoxic, normally functioning heart (114). Thus, by this approach, a tracer has emerged that warrants in vivo evaluation as a cardiac hypoxia imaging agent specifically tuned to detect hypoxia at levels relevant to cardiac disease.

4.3 Cell Tracking with Copper

We have seen above that CuBTSC complexes can be tuned to give redox potentials and lipophilicities suited to imaging of blood flow and hypoxia. The bioreductive intracellular trapping mechanism of CuBTSC complexes lends itself to further applications. One, at least conceptually, is cell labeling for cell tracking with $^{64}$Cu, similar to that described above for $^{89}$Zr. The aim in cell labeling is to incorporate $^{64}$Cu into cells nonspecifically and as efficiently as possible, and ensure that it is retained within the cell for the required duration of the in vivo tracking (i.e., ideally at least two half-lives). The BTSC complexes offer a simple solution to this: by choosing ligands that will give efficient reduction and trapping regardless of oxygen levels, it should be possible to achieve labeling of any cell type. Several groups have used $^{64}$CuPTSM (118–120), as it is the most well-known of the non-hypoxia-selective BTSC ligands; however, the data in Figure 10 show that its trapping is not completely independent of hypoxia, while the cyclic voltammetry results described earlier suggest that $^{64}$CuGTSM might have even more efficient cell labeling properties. Labeling human cancer cell lines
with $^{64}$CuGTSM indeed proved to be more efficient and rapid compared to $^{64}$CuPTSM and other $^{64}$CuBTSC complexes, with around 80% of radioactivity taken up in cultured cells of different types within a few minutes (121). Unfortunately, irrespective of which $^{64}$CuBTSC complex was used (CuPTSM, CuGTSM, and others), the radioactivity quickly washed out of the cells, with only about 20% of the initially trapped activity remaining by 24 h. Switching to an alternative form of bioreducible lipophilic complex—copper(II) bis(dithiocarbamate) complexes—produced similar very high labeling efficiencies but a similar rate of efflux (121). Thus, while the efficiency of labeling varied substantially with different BTSC and dithiocarbamate ligands, the rate of efflux was unaffected by the complex used. This is consistent with the original hypothesis that the complex undergoes dissociation within the cell, and once this has occurred the fate of the copper is independent of the chelator. The copper is excreted from the cell by equilibrium or native copper trafficking systems. Several authors, although often describing $^{64}$CuPTSM as a “successful” cell tracking PET agent, have reported similar experiences (118–120), and it must be concluded that relying on intracellular dissociation of copper complexes is inadequate for long-term cell tracking experiments, despite having been successful for $^{111}$In and $^{89}$Zr (perhaps because indium and zirconium are “abiological” elements and have no specific biological cellular trafficking mechanisms). If radiocopper is to be used for cell tracking, alternative methods must be found.

### 4.4 Copper Trafficking Pathways in Health and Disease

The failure of $^{64}$CuBTSC complexes as cell tracking labels is likely to be a result of the $^{64}$Cu being subject to native cellular transport mechanisms for copper. This same feature offers an alternative application of copper isotopes: using PET to study disease-related changes in the transport and metabolism of copper. Several diseases are characterized (as cause or consequence) by altered copper metabolism, including Wilson’s disease, Menkes’ disease, Niemann–Pick disease, various dementias, and nutritional abnormalities. $^{64}$Cu transport changes have also recently been observed in some tumor models (122). $^{64}$Cu has barely been used for this purpose so far. $^{64}$Cu can be administered via different routes (diet, intravenously, hepatic portal vein, etc.) and in different forms (ionic copper, albumin, ceruloplasmin, etc.) to elucidate transport pathways by which copper can reach cells.
In addition, the ability of $^{64}$CuGTSM to deliver $^{64}$Cu nonselectively to all cells could be used to bypass these delivery systems and allow the efflux of copper from different tissues in health and disease to be studied. We have recently demonstrated this approach in a mouse model of Alzheimer’s disease. When $^{64}$Cu acetate is administered intravenously to mice, delivery to brain is very low and focused in the ventricular regions of the brain (Figure 11). However, when $^{64}$CuGTSM is administered by the same route, much more is taken up in brain and the uptake is global; there is also high uptake in all other tissues with high blood flow, especially the myocardium (Figure 11). Intriguingly, the initially trapped activity in most tissues (notably the heart and lungs) is rapidly cleared over a few hours, but clearance from the brain is very low indeed. In the Alzheimer’s disease model, while

![Figure 11 PET/CT whole body distribution (lower images) of $^{64}$Cu in normal mice 30 min after intravenous administration of $^{64}$CuGTSM (left) and unchelated (right) $^{64}$Cu(II) (acetate salt). The upper images show sagittal and coronal close-ups of the brain showing high global uptake in brain for CuGTSM but focal uptake restricted to the ventricle regions for ionic copper. The graph shows $^{64}$Cu concentration 30 min and 24 h after injection of $^{64}$CuGTSM in brains of genetically modified mice with Alzheimer’s-like pathology (red broken lines (light gray in the print version)) with that in their normal counterparts (blue lines (dark gray in the print version)).](image)
uptake in brain was increased compared to normal controls, clearance from brain between 30 min and 24 h was accelerated fivefold (Figure 11), although this was still much slower than from other tissues (123). This study provides an example of the potential for use of copper radionuclides to study abnormalities in copper metabolism related to disease. Many applications of this approach can be imagined.

5. INORGANIC ELEMENTS AS BINDING SITES FOR \(^{18}\)F-FLUORIDE

PET radiochemistry with fluorine-18 is traditionally regarded as the preserve of organic chemists. However, recently a novel inorganic approach to labeling biomolecules with \(^{18}\)F has emerged in which a coordinatively unsaturated aluminum complex is used as a high-affinity binding site for fluoride. Bifunctional molecules containing other elements with a high affinity for fluoride, including silicon and boron, have also been used for biomolecule labeling (5). We have used this approach to develop an \(^{18}\)F-labeled PET agent for imaging the activity of the human sodium/iodide symporter (hNIS), for diagnosis of thyroid disease and for imaging hNIS when used as a reporter gene. Thyroid cancer and abnormal thyroid function have been a mainstay activity in nuclear medicine for half a century, using gamma-emitting isotopes \(^{131}\)I and \(^{123}\)I in the form of iodide. Iodide is the natural substrate of hNIS, which pumps it into the cell driven by the concentration gradient of sodium ions across the cell membrane. \(^{99m}\)Tc imaging of hNIS is also routinely used, as the pertechnetate ion is also an efficient hNIS substrate, although unlike iodine it is not metabolically trapped within the thyroid. The advantages of PET imaging of thyroid disease have been sought by use of the positron emitter \(^{124}\)I, but the half-life of this isotope (4.2 days) is excessive and the positron yield is low, while unwanted gamma emissions are high; all these features contribute to excessive radiation dose to patients and inferior quality imaging. A tracer labeled with \(^{18}\)F would be advantageous in all these respects, as well as being very readily available. The tetrafluoroborate ion is a substrate of hNIS, and we have developed an effective method of producing \(^{18}\)F-labeled BF\(_4^-\) with a yield and specific activity sufficient for clinical PET imaging. Preclinical imaging in mice demonstrated excellent target-to-background ratios and excellent quality images, with greatly increased uptake in a thyroid tumor model. Specificity for hNIS as the mechanism of uptake was demonstrated by administering
perchlorate, which is a competitive inhibitor/substrate of hNIS (Figure 12) \cite{124,125}. This new thyroid PET imaging agent is now undergoing clinical trials in patients with thyroid cancer and salivary gland cancer.

6. MULTIMODALITY IMAGING AND NANOPARTICULATE CONTRAST AGENTS

Much of the new chemistry described in this chapter has been driven by a shift in imaging technology toward PET during the last 20 years (which was in turn driven by the importance of the glucose tracer FDG, which has no gamma-emitting analog). Currently another shift in technology is underway, in which different imaging modalities are combined so that they may complement each other to overcome limitations of the individual modalities. For example, PET and SPECT have exquisite sensitivity (that is, very small amounts of contrast agent—subpicomolar concentrations in vivo—are required to produce images) and they provide truly “molecular” imaging; however, they suffer from poor resolution (ca. 1 cm in humans). Magnetic resonance imaging (MRI), on the other hand, offers much better anatomical

Figure 12 Biodistribution of $^{18}$F-tetrafluoroborate by PET/CT imaging. Left: normal mouse showing thyroid and stomach uptake and excretion into bladder; center: mouse with implanted NIS-expressing breast tumor showing tumor (T) uptake as well as thyroid (Th) and stomach (S) uptake; right: normal mouse preinjected with perchlorate to block NIS activity, showing radioactivity largely confined to blood pool.
resolution but its molecular imaging capability is restricted by the large amounts of contrast agent required (ca. milli/micromolar in vivo) because of its poor sensitivity. Optical imaging can be used at both the whole body (at least in small animals) and cell level, whereas radionuclide imaging cannot; but optical imaging is severely restricted in its clinical use by scatter and poor tissue penetration of visible light; combining the two can therefore provide cellular mechanistic information to help interpret whole body scanning. A new generation of scanners combining PET and MRI is now entering clinical use, and once again this new technology is driving new chemistry to produce combined modality contrast agents.

One approach to combined radionuclide and magnetic contrast agents is to incorporate radionuclides into magnetic nanoparticles (e.g., superparamagnetic iron oxide nanoparticles (SPION)) and other nonmagnetic inorganic materials. Nanoparticles have potential in specific niche areas of imaging such as sentinel lymph node localization (126), imaging the reticuloendothelial system (liver, spleen, bone marrow), exploiting the enhanced permeability and retention (EPR) effect associated with the disorganized neovascularure of tumors, cell labeling (81) and imaging liposome-mediated drug and gene delivery (127). To produce a stable and versatile link between radionuclide and nanoparticle surface, we have adopted an approach of devising chemistry that links directly to the inorganic material rather than the conventional approach of embedding the particles in an organic or silica matrix. We have found that the bisphosphonate group, well-established as a means of targeting bone mineral metabolism with radionuclides (in part because of the high affinity of bisphosphonates for hydroxyapatite), forms very high affinity and kinetically stable links with the surface of SPIONs (much more stable than the conventionally used carboxylate groups). This has been exploited by means of the dipyridylamino- and dithiocarbamato-bisphosphonate conjugates described above (Figure 3). The dpa-bisphosphonate was used to link the $^{99m}$Tc(CO)$_3^+$ core to iron oxide-based nanoparticles, creating a dual modality SPECT/MRI contrast agent (18). A clinical trial to evaluate the advantages of this combination in breast cancer surgery (including intraoperative use of a hand held magnetometer to help locate the sentinel node) is now underway, using presurgical SPECT and MRI to locate sentinel lymph nodes (using the high sensitivity of the SPECT component) and to elucidate their internal structure and detailed local anatomy (using the MRI component). The SPION-bisphosphonate interaction can also be used to modify the surface of the nanoparticles to
control their clearance half-life in blood (by attaching polyethylene glycol (PEG)) (17) and potentially to add molecular targeting capability. The dithiocarbamate-bisphosphonate conjugate, described above for synthesis of a $^{99m}$Tc–divalent bisphosphonate complex for imaging calcification (Figure 3), was used to produce a $^{64}$Cu bis(dithiocarbamate) complex 55, also with two pendant bisphosphonate groups, that afforded extremely stable binding of $^{64}$Cu to the iron oxide surface (Figure 13), allowing combined modality PET and MRI of lymph nodes in vivo (128).

A second approach to the design of nanoparticulate contrast agents is to identify materials for the fabrication of nanoparticles in which the material itself has a high affinity for the most useful radionuclides—notably $^{18}$F-fluoride. Several inorganic nanoparticulate materials have been identified that bind fluoride with high affinity and stability, in some cases with extraordinary capacity and very simple labeling procedures (129). The

**Figure 13** Top: incorporation of $^{64}$Cu into iron oxide nanoparticles exploiting the affinity of copper complexes with pendant bisphosphonate groups (55) to the mineral surface. Bottom left: MRI images before (left) and after (right) injection of labeled particles into the footpads of a mouse, showing translocation of particles into lymph nodes indicated by arrows (as identified by loss of signal in the lymph nodes in the right image). On the right is a PET/CT image showing the location of $^{64}$Cu in the same lymph nodes as the MRI contrast.
leading candidates were hydroxyapatite and aluminum hydroxide. As well as providing readily labeled particulates for PET imaging, these materials can be coated onto SPIONs to afford the advantages of combined MRI and radionuclide imaging, by constructing core–shell nanoparticles with an iron oxide–based material encapsulated in a biocompatible shell of aluminum hydroxide (23) or hydroxyapatite (130), both of which are biocompatible and endow the particles with high affinity for $^{18}$F-fluoride. These shell materials also have a high affinity for bisphosphonate groups, so that the radiolabeled or PEG–linked bisphosphonate derivatives can also be used to radiolabel or modify their surfaces. Similarly, these materials can also be rendered fluorescent for optical imaging by attaching fluorophores covalently linked to bisphosphonate groups, yielding versatile trimodality contrast agents.

The complementarity of optical and radionuclide imaging is important to enable correlation of imaging at the whole body level with cellular imaging at the microscopic level. This is valuable in the basic study of cell trafficking processes such as cancer metastasis and the migration of immune cells and stem cells. Imaging tools to exploit this, both for basic biomedical studies in animal models and for application in clinical trials of cellular therapies, are sought after. In principle, cells can be engineered genetically to express a “reporter gene” which enables them to be detected by means of an imaging technique to show their location and function/survival in the body (131). The sodium/iodide symporter (hNIS) is an excellent example of such a gene because its expression in the host is restricted mainly to thyroid and stomach and it can be imaged with a wide range of simple radiotracers (iodine isotopes as described above, $^{99m}$Tc–pertechnetate, and now $^{18}$F-tetrafluoroborate, Figure 12, center image). We have combined this with fluorescence imaging by creating a gene encoding a fusion protein combining both hNIS and a red fluorescent protein, and demonstrated the value of the combined modality SPECT/PET and optical imaging by detecting micrometastases with extremely high sensitivity in a cancer animal model, using $^{99m}$Tc–pertechnetate SPECT (132) and $^{18}$F-tetrafluoroborate PET.

7. SUMMARY AND CONCLUSION

The development of medical imaging is a highly multidisciplinary endeavor requiring the close cooperation of clinicians, physicists, engineers, biologists, and chemists to identify capabilities, conceive challenges and
solutions and apply them in the clinic. The chemistry described in this chapter illustrates how synergistic advances in these areas drive the technology and its applications forward, with each discipline producing innovations that in turn drive innovations in the others. The main thread running through this chapter is the shift from single photon radionuclide imaging toward PET, and in turn the emerging shift from PET/CT toward PET/MRI and further, combination of these with optical imaging. At the same time, a renaissance of development of technetium chemistry may be anticipated by renewed confidence in the supply of $^{99m}$Tc and the unmet need for simpler methods of radio-labeling compatible with biomolecular targeting. This would mimic progress in the current development of simple chemistry to exploit the $^{68}$Ga generator, and methodology for cell tracking in the new era of cellular therapies. A slowing down of inorganic chemical innovation for application in medical imaging is not anticipated.

ACKNOWLEDGMENTS

The authors are grateful to Dr. Kavitha Sunasee and Mr. Stephen Clarke for assistance with small animal imaging. This research was supported grants from the Alzheimer’ Society, Alzheimer's Research UK, Leukaemia and Lymphoma Research, Cancer Research UK, EPSRC, by the Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC under grant number WT088641/Z/09/Z, and the King’s College London and UCL Comprehensive Cancer Imaging Centre funded by CRUK and EPSRC in association with the MRC and DoH (England), and by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London. PET and SPECT scanning equipment was funded by an equipment grant from the Wellcome Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

REFERENCES

42. Surfraz, M. B.-U.; Biagini, S. C. G.; Blower, P. J. *Dalton Trans.* **2008**, *2920*.
64. Ma, M. T.; Cullinane, C.; Imberti, C.; Bagun˜a-Torres, J.; Terry, S. Y. A.; Roselt, P.; Hicks, R. J.; Blower, P. J. Bioconjugate Chem. 2015, 26, in press.
77. Ma, M. T.; Meszaros, L. K.; Paterson, B. M.; Berry, D. J.; Cooper, M. S.; Ma, Y.; Hider, R. C.; Blower, P. J. Dalton Trans. 2015, 44, 4884.
100. Castle, T. C.; Maurer, R. I.; Sowrey, F. E.; Went, M. J.; Reynolds, C. A.; McInnes, E. J. L.; Blower, P. J. J. Am. Chem. Soc. 2003, 125, 10040.


